Table 2

 Procedural characteristics and radiation therapy details

Number (%)
*138 of these patients were enrolled in the RENO (radiation in Europe with Novoste) study; †stepwise administration; ‡patients who had delay between intervention and the administration of brachytherapy.
BERT, beta energy restenosis trial; BRIDGE, β radiation investigation with direct stenting and Galileo in Europe; BRIE, beta radiation in Europe; Gp, glycoprotein; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; LM, left main coronary artery; PREVENT, proliferation reduction with vascular energy trial; RCA, right coronary artery; START, stents and radiation therapy; SVG, saphenous vein graft.
Patients301
Follow up (range) (years)3.6 (1.2–5.9)
One vessel treated273 (90.7%)
Two vessels treated28 (9.3%)
Total number of vessels329
Failed radiation4 (1.3%)
Second radiation4 (1.3%)
Vessel treated
    LM2 (0.6%)
    LAD120 (36.5%)
    RCA115 (35.0%)
    LCx73 (22.2%)
    SVG19 (5.8%)
Dual antiplatelet treatment
    None51 (16.9%)
    1–3 months71 (23.6%)
    6 months142 (47.2%)
    >6 months37 (12.3%)
Gp IIb/IIIa inhibitors109 (36.2%)
Study
    BERT30 (10.0%)
    Beta-Cath trial13 (4.3%)
    BRIDGE11 (3.7%)
    BRIE14 (4.7%)
    Compassionate use23 (7.6%)
    EURO-START 4012 (4.0%)
    PREVENT29 (9.6%)
    Routine use*169 (56.1%)
Source
    32P40 (13.3%)
    90Sr/90Y261 (86.7%)
Source length (vessels) (mm)
    32P: 2740 (12.2%)
    90Sr/90Y: 30142 (43.2%)
    90Sr/90Y: 40109 (33.1%)
    90Sr/90Y: 6038 (11.6%)
Tandem radiation†48 (14.6%)
Delayed radiation‡7 (2.1%)